MR MultinuclearNCT07368036
MR 7700 Multinuclear Application Clinical Trial
A study testing MR Scanning with Phosphorus nucleus + Sodium nucleus in people with MR Multinuclear and Image Quality, run by Philips Clinical & Medical Affairs Global.
Trial summary
The purpose of this clinical trial is to use the medical magnetic resonance imaging system MR 7700 to perform phosphorus (31P) and sodium (23Na) scanning imaging on the human body, evaluate the image quality of phosphorus (31P) and sodium (23Na) scanning, as well as the machine convenience, machine stability, and… Read more about this study
- Who is it for?
- Ages 18 to 75 yearsHealthy volunteers can take part
- Conditions the study is for
- MR Multinuclear, Image Quality, Device Convenience
- What is being tested?
- MR Scanning with Phosphorus nucleus + Sodium nucleus
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 200 participants
- Where
- No sites listed yet
- Study dates
- 1 Mar 2026to 31 Oct 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- • 18 ≤ Age ≤ 75 years old;
- Clear mind, able to cooperate, and capable of autonomous behavior;
- Voluntarily agree to participate in this clinical trial and sign the informed consent form for the subjects
Who cannot join
- • Individuals with claustrophobia.
- On the day of scanning, the subject's body temperature was above 39.5 ℃.
- Plan to become pregnant, pregnant, and breastfeeding women within 6 months.
- Other implants, prostheses, foreign bodies, patches, etc. that are not suitable for magnetic resonance imaging examination; There are electronic implants such as pacemakers, stimulators, insulin pumps, cochlear implants, etc.
- Critical patients equipped with various rescue devices, as well as subjects with any emergency medical conditions requiring first aid.
- Subjects with poor compliance, which the researchers believe should be excluded.
- Other situations that the investigators believe are not suitable for participating in this experiment.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: MR 7700 Multinuclear Application Clinical Study
The purpose of this clinical trial is to use the medical magnetic resonance imaging system MR 7700 to perform phosphorus (31P) and sodium (23Na) scanning imaging on the human body, evaluate the image quality of phosphorus (31P) and sodium (23Na) scanning, as well as the machine convenience, machine stability, and system safety of the entire system.
- Being tested
- MR Scanning with Phosphorus nucleus + Sodium nucleus
- Keywords
- multinuclear, MR
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MR Scanning with Phosphorus nucleus + Sodium nucleusDevice
Using the Magnetic Resonance Equipment to perform phosphorus nucleus (31P) and sodium nucleus (23Na) scanning
| Study group | Role | What they receive |
|---|---|---|
| Healthy volunteers | Experimental | Not described Receives: Device: MR Scanning with Phosphorus nucleus + Sodium nucleus |
| Patient | Experimental | Not described Receives: Device: MR Scanning with Phosphorus nucleus + Sodium nucleus |
What is being measured
The primary outcome is the main question the study is designed to answer.
The excellent and good rate of Spectral image quality of 31P-MRS
Spectral image quality of phosphorus nucleus (31P) in each site (muscle, liver, heart)，will be assessed by Likert score (1-5) .
The final evaluation of image quality at 3 points or above is considered excellent and good.The rate of excellent and good should be over 75%.
Measured: 14 days (anticipated) after finishing 31P-MRS scanning
The excellent and good rate of image quality of 23Na-MRI
Image quality of sodium nuclei (23Na) in each site (liver, cartilage), will be assessed by Likert score (1-5) . The final evaluation of image quality at 3 points or above is considered excellent and good.The rate of excellent and good should be over 75%.
Measured: 14 days (anticipated) after finishing 23Na-MRI scanning
Secondary outcomes (4)
The Device convenience of the entire system
A three-scale assessment will be used for evaluate the device convenience of the entire system from the aspects of subject positioning, scanning interface, scanning sequence, image processing, microphone communication, and image storage/transmission and management.
A three-scale criteria- Satisfied, General, Dissatisfied Assessment criteria: The parameters should all reach "General or Satisfied", indicating that the case meet the device convenience.
Measured: 14 days (anticipated) after finishing scanning
Device stability
Evaluate the stability of the device from the aspects of system startup, system shutdown, abnormal interruption during scanning, image display after scanning, and missing image reconstruction.
A three-scale criteria- Satisfied, General, Dissatisfied. Assessment criteria: The parameters should all reach "General or Satisfied", indicating that the case meet the device stability.
Measured: 14 days (anticipated) after finishing scanning
System security
The technician observes whether there are any system safety issues during the scanning of each image instance After the scan, a "yes" or "no" judgment is made based on the occurrence of each assessment item. If all assessment items are rated as "none", it indicates that the system is safe.
Measured: 14 days (anticipated) after finishing scanning
Adverse event
Analyze the adverse events during the clinical trial process, summarize and analyze the frequency and percentage of all adverse events (including serious adverse events) in a list, and classify them based on their correlation with the device.
Measured: From the time the subjects signed the ICF to completion of study visit(1 day).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Jan 2026
- Study start1 Mar 2026 (estimated)
- Primary completion31 Aug 2026 (estimated)
- Study completion31 Oct 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for MR MultinuclearStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Philips Clinical & Medical Affairs Global
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07368036
- Sponsor's protocol ID
- 300957
- Status last verified
- Jan 2026
- First submitted
- 1 Dec 2025
- Last updated
- 26 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 26 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- MR 7700 Multinuclear Application Clinical Study
- ClinicalTrials.gov ID
- NCT07368036
- Acronym / sponsor ID
- 300957
- Keywords
- multinuclear, MR
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Philips Clinical & Medical Affairs GlobalIndustry (pharma, biotech, devices)
- Study start
- 1 Mar 2026 (estimated)
- Primary completion
- 31 Aug 2026 (estimated)
- Study completion
- 31 Oct 2026 (estimated)
- First posted
- 26 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this clinical trial is to use the medical magnetic resonance imaging system MR 7700 to perform phosphorus (31P) and sodium (23Na) scanning imaging on the human body, evaluate the image quality of phosphorus (31P) and sodium (23Na) scanning, as well as the machine convenience, machine stability, and system safety of the entire system.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Healthy volunteers | Experimental | Device: MR Scanning with Phosphorus nucleus + Sodium nucleus |
| Patient | Experimental | Device: MR Scanning with Phosphorus nucleus + Sodium nucleus |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- • 18 ≤ Age ≤ 75 years old;
Key exclusion criteria (7 listed)
- • Individuals with claustrophobia.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MR Scanning with Phosphorus nucleus + Sodium nucleusUsing the Magnetic Resonance Equipment to perform phosphorus nucleus (31P) and sodium nucleus (23Na) scanning | Device | Healthy volunteers, Patient |
Primary outcome
The excellent and good rate of Spectral image quality of 31P-MRS
Time frame: 14 days (anticipated) after finishing 31P-MRS scanning
Spectral image quality of phosphorus nucleus (31P) in each site (muscle, liver, heart)，will be assessed by Likert score (1-5) . The final evaluation of image quality at 3 points or above is considered excellent and good.The rate of excellent and good should be over 75%.
The excellent and good rate of image quality of 23Na-MRI
Time frame: 14 days (anticipated) after finishing 23Na-MRI scanning
Image quality of sodium nuclei (23Na) in each site (liver, cartilage), will be assessed by Likert score (1-5) . The final evaluation of image quality at 3 points or above is considered excellent and good.The rate of excellent and good should be over 75%.
4 secondary outcomes
The Device convenience of the entire system
Time frame: 14 days (anticipated) after finishing scanning
Device stability
Time frame: 14 days (anticipated) after finishing scanning
System security
Time frame: 14 days (anticipated) after finishing scanning
Adverse event
Time frame: From the time the subjects signed the ICF to completion of study visit(1 day).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Jan 2026.
- Individual participant dataSharing planned: Undecided
Related trials for MR Multinuclear
Not yet recruiting
MR 7700 Multinuclear Application Clinical Study
Hepatocellular Carcinoma, MRI
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
A study testing MR Scanning with Phosphorus nucleus + Sodium nucleus in people with MR Multinuclear and Image Quality, run by Philips Clinical & Medical Affairs Global.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 26 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Bing Zhang ((+86)15851803070, zhangbing_nanjing@vip.163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The excellent and good rate of Spectral image quality of 31P-MRS (time frame: 14 days (anticipated) after finishing 31P-MRS scanning). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Jan 2026.